echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Science News > Successful construction of a pig model of human metabolic inflammation

    Successful construction of a pig model of human metabolic inflammation

    • Last Update: 2021-08-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Successful construction of a pig model of human metabolic inflammation
    The pig model of human metabolic inflammation was successfully constructed.


    The liver and fat of a humanized mini-pig model of metabolic diseases show similar molecular characteristics of triggering metabolic inflammation as humans.
    Image courtesy of the Chinese Academy of Agricultural Sciences

     The liver and fat of a humanized mini-pig model of metabolic diseases show similar molecular characteristics of triggering metabolic inflammation as humans.
    Image courtesy of the Chinese Academy of Agricultural Sciences

    Recently, the animal genetic engineering and germplasm innovation technology innovation team of Beijing Institute of Animal Husbandry and Veterinary Medicine, Chinese Academy of Agricultural Sciences successfully constructed a pig model of human metabolic inflammation, providing important experimental materials for human metabolic inflammation translational medical research
    .
    Related research results were published in " Frontiers in Immunology " ( Frontiers in Immunology )


    .


    Frontiers in Immunology

    According to researcher Yang Shulin of the institute, chronic, low-grade inflammation caused by overnutrition is the common pathogenesis of metabolic diseases such as obesity-related type 2 diabetes, non-alcoholic fatty liver disease, and atherosclerosis
    .
    Due to the huge immunological differences between rodents and humans, the efficiency of the conversion and application of related therapeutic drugs from trials to clinics is limited


    .


    The research team used multi-gene targeted integration technology to transfer three human metabolic disease susceptibility genes (GIPRdn, hIAPP and PNPLA3I148M) into the pig genome
    .
    The tissue-specific promoter regulates the expression of GIPRdn and hIAPP in pancreatic β-cells, and regulates the expression of human PNPLA3I148M in the liver.


    This pig model exhibits pathological features such as impaired glucose tolerance, fatty pancreas, fat, and chronic liver inflammation


    Through homology comparison of the protein sequences of 30 genes that play a key role in the process of inflammation, it is found that the similarity of 24 genes between pigs and humans is higher than that between rodents and humans.


    The results show that the pig model fat and liver metabolic inflammation trigger and cascade molecular characteristics are highly similar to humans, and it is suitable as an experimental material for clinical translational medicine research


    Related paper information: https://doi.


    https://doi.
    org/10.
    3389/fimmu.
    2021.
    690069
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.